• Sarah Howell, Ph.D., Chief Executive Officer

    Sarah Howell was appointed Chief Executive Officer of Arecor in 2015, having joined in 2011 as Chief Operating Officer and Executive Director. During her time at Arecor she has led the transformation of the business into a successful clinical stage biotechnology company. Sarah has a background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas.

    She has served in a number of senior roles in the pharmaceutical industry, including Vice President CMC & Technical Development at BTG Plc., and Director of Outsourced Manufacturing at UCB-Celltech.

    Sarah holds a BSc in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.

  • Susan Lowther, Chief Financial Officer and Company Secretary

    Susan Lowther was appointed Chief Financial Officer and Company Secretary at Arecor in 2019. She brings significant financial leadership experience across a broad range of public and private life science companies. Susan joined Arecor from IXICO plc, an imaging contract research organisation where she defined the financing strategy and raised growth capital taking the company on a path to profitability.

    Previously, she was Chief Financial Officer at Novacyt S.A. where she oversaw the acquisition of Lab21 Limited, CFO at BioWisdom Limited, who were acquired by Instem Plc, and Finance Director of RiboTargets Limited, from start-up until its acquisition by Vernalis plc.

    Susan’s life-sciences career started at Celltech Group plc and included Head of Finance at Lonza Biologics (previously Celltech Biologics). As part of the leadership team, she was responsible for finance, HR, IT and facilities functions in the US and UK.

    Susan has been a member of executive boards since 1997 and a Fellow of the Chartered Institute of Management Accountants since 2003.

  • Jan Jezek, Ph.D., Chief Scientific Officer

    Jan Jezek has been Chief Scientific Officer of Arecor since 2007 and has led R&D for the proprietary protein stabilisation technologies of the company’s Arestat™ platform and their application to commercial therapeutic products. Jan is responsible for R&D activities, platform development and IP strategy.

    Previously, he was a Principal Scientist at Insense Limited, a spin-out from Unilever, where he was responsible for the development of novel medical devices, taking them from concept to market.

    Jan holds a joint Doctorate from the University of Bedfordshire and the University of Chemical Technology, Prague. He is a member of the Scientific Advisory Board of the Centre of Excellence in Biopharmaceuticals (University of Manchester) and is an active member of the Formulation Science & Technology Group (FSTG) at the Royal Society of Chemistry and the Biopharmaceutical Group at the Academy of Pharmaceutical Sciences (APS).

  • David Gerring, VP, Development

    David has 15 years’ experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience. He is VP, Development at Arecor, with a wide range of responsibilities, including: scientific strategy, project management, facilities, health & safety, quality and client procurement, grant and internal product development management.

    He has held senior roles at Immunocore and Emergent BioSolutions and his experience includes 5 years at UCB, whilst in a scientific and regulatory capacity. There, he focused on the development and successful licensure of Cimzia. He headed up process and analytical development at BTG, managing CMC for several recombinant products, including successful INDs and licensures.




  • Fiona Lawrence, VP, Clinical & Regulatory Affairs and QA

    Fiona Lawrence is a pharmaceutical research and development professional and, as VP, Clinical & Regulatory Affairs and QA at Arecor, she has responsibility for driving the clinical development of Arecor’s proprietary portfolio.

    She has experience from across the biotechnology, pharmaceutical, public and not-for-profit/charitable sectors. Previously, she was Director of Research and Clinical Development at Duchenne UK with responsibility for developing the research strategy for the charity. She spent five years at BioMarin and Prosensa in Leiden, working as Senior Clinical Research Manager and four years as Commercial Trials Manager at Cambridge University Hospitals.

    Fiona holds an M.Sc. in Pharmaceutical Medicine from the University of Surrey and a B.Sc. in Pharmacology from the University of Bath.